MGMT and central nervous system cancer: In order to improve the accuracy of diagnosis and treatment of gliomas, the European Association of Neuro-Oncology (EANO) incorporated molecular markers such as IDH mutation (IDH-mu), chromosome 1p or 19q co-deletion (1p/19q-codel) and MGMT promoter methylation (MGMTp-M) into the diagnostic guidelines for gliomas [10].